Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 40
Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 121
Stat of the Week: Home Health & Hospice -27%
Mergers and acquisitions in the home health and hospice sector have continued a downward spiral, beginning in Q1:17. 2016 ended with 62 deals, which was a healthy rebound following a lackluster performance in 2015. The sector also experienced growing interest from financial buyers in that time. But, as of September 21, only 33 deals have been publicly announced, down 27% from the 45 deals announced in the same period last year. Based on disclosed prices, only $20.95 million has been spent, down 98% from the same period in 2016, when $1.0 billion had been committed to finance those deals. The bulk of this year’s spending total comes from a deal announced on March 1 by Amedisys, Inc.... Read More »
AAC Adds Addiction Treatment in New England
AAC Holdings, Inc. (NYSE: AAC), operator of American Addiction Centers, announced its first acquisition of 2017. The company is ramping up again after a hot streak in 2015, when it acquired seven companies for a combined $143 million. Since then, the once-serial acquirer has been quiet on the M&A front as it integrated all its new businesses. It resurfaced briefly in April 2016, when it purchased a sober living facility in Texas for $5 million. Then, on September 13, AAC announced its biggest deal to date. The target, AdCare, Inc., provides addiction treatment in New England. It operates a 114-bed hospital for substance abuse treatment and five outpatient centers in Massachusetts, as... Read More »
Private Equity Feeds RCM Growth
Revenue cycle management companies remain a strong investment opportunity for financial buyers. As of Mid-September 2017, 52% of RCM targets were acquired by private equity firms or other PE-backed eHeath companies. One Georgia-based RCM firm continues to thrive following an investment from Bain Capital. In June 2016, Bain Capital acquired Navicure Inc. for an undisclosed price. Navicure provides cloud-based claims management and patient payment solutions for physician practices and hospitals. Its revenue cycle management platform served approximately 90,000 U.S. providers at the time of the deal. Fast forward to September 2017, Navicure now serves more than 100,000 providers. On... Read More »
Teva Begins to Pare Its Portfolio
Last week, Teva Pharmaceutical Industries Ltd. (NYSE: TVA) divested more than $1.1 billion of assets in response to increasing financial pressure. Just this August, Credit Suisse lowered its rating on Teva’s stock from neutral to underperform, citing industry-wide pricing pressure for generic drugs. Credit Suisse’s announcement follows Teva’s acquisition of Allergan’s (NYSE: AGN) generic division, Anda Inc., just a year ago, for $500 million. Teva is looking to pay down more than $35 billion in debt–an amount that exceeds its market value. To do so, the Israeli drug maker has pursued divestiture opportunities for its global Women’s Health business, as well as its Oncology and... Read More »
Deal of the Week: Centene/Fidelis Care
Centene Corporation (NYSE: CNC), the self-declared leader in government-sponsored healthcare in the U.S., has taken over another state. As larger rivals like Anthem (NYSE: ANTM) and UnitedHealth Group (NYSE: UNH) quit the individual health insurance exchanges around the country, Centene has marched in. In its first major deal since July 2015, Centene is now tops in New York State, thanks to its $3.75 billion deal for not-for-profit Fidelis Care. Fidelis Care provides health insurance coverage through Qualified Health Plans, Child Health Plus, Essential Plan, and Medicaid, available through the New York State of Health Marketplace, as well as through the Medicare Advantage, Dual Advantage,... Read More »
Stat of the Week: Behavioral Health Care, +12%
Mergers and acquisitions in the Behavioral Health Care sector have been on a tear in recent years, relatively speaking. The caveat is that many deals are done locally, between private or not-for-profit organizations, and most are not publicly announced. Private equity firms have been piling into this space, and they aren’t known for a lot of transparency around portfolio companies, unless they’re touting their platform-building prowess. Through mid-September, M&A activity in this sector stands at 37 deals, up 12% compared with the same period in 2016 (33 deals then). Dollar values haven’t kept up the pace, however. Just $554 million in financing has been publicly... Read More »Stat of the Week: M&A in 2017
Since July, we’ve seen several headlines in the trades regarding deal making activity in various healthcare sectors. We’ve also attended several conferences and forums focused on healthcare deal making. What we hear at those conferences is usually closer to the truth than what we’ve read. It may be all about the methodology, but here’s our take on overall deal volume and value in 2017, through August 31. Last year, 2016, set a new record in overall deal volume among the 13 sectors we track in our Deal Search Online database. The combined total of deals for last year stands at 1,568, only 2% greater than the 1,530 announced in 2015. This year could be even better, if... Read More »
August Marks the Return of the Big Deals
The dog days of summer weren’t really all that hot, here in the Northeast. Neither was August’s deal volume. Although it’s preliminary data, the 102 deals posted in August equalled the total in July. Compared with the same month in 2016, that represents a 22% slide in deal volume. But don’t fret, deal-meisters. We saw several billion-dollar deals last month, which lifted August 2017’s spending to $22.3 billion. That’s 156% higher than the previous month, and just 1% below the $22.6 billion recorded a year ago. Once again, the Biotechnology sector was the big money-maker. Deal volume was up 30%, year over year, to a modest 13 deals. The largest deal announced in August was Gilead Sciences’... Read More »Deal of the Week: Teleflex/NeoTract
The Deal of the Week (ended Sept. 8, 2017) is also the largest announced in the holiday-shortened work week. Teleflex Incorporated (NYSE: TFX) announced its first acquisition this year, paying $725 million upfront for privately held NeoTract, Inc. It marks a new focus for the medical device maker, whose previous buyouts concentrated in cardiovascular and microlaparoscopy surgical technologies. NeoTract is a medical device maker that has developed and commercialized the FDA-cleared UroLift System, a novel, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia, or BPH. Anyone who watches professional sports televised on Sunday afternoons... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
